Efficacy and safety of transarterial chemoembolization + vitamin K combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study
Phase 2
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000026404
- Lead Sponsor
- Osaka General Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 101
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who underwent previous transarterial chemoenmbolization greater than twice, patients with warfarin dosing, patients who have been given vitamin K before the enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method